University of Maryland School of Medicine Study Sheds New Insight into Causes and Potential Treatment for Placental Disorders like Preeclampsia and Preterm Birth
About 1 in 10 pregnant women experience placenta abnormalities that lead to life-threatening preeclampsia (hypertension), preterm labor and fetal growth problems, but finding effective treatments to effectively prevent or reverse these conditions has so far been elusive.
A new finding from University of Maryland School of Medicine (UMSOM) researchers, published in the June issue of the journal Endocrinology, could have important implications for developing novel treatments to prevent placental abnormalities. The study, which involved female non-human primates, provided confirmatory evidence that elevated levels of the female hormone estrogen early in pregnancy leads to abnormalities in the uterine artery that lessens blood flow to the placenta, providing less nourishment to the fetus. Instead of adapting to the increased blood flow of pregnancy by becoming more pliant -- known as uterine artery remodeling -- the arteries remain rigid when estrogen levels are elevated, which impedes blood flow and oxygen delivery to the placenta and, in turn, to the fetus.
More importantly, the researchers demonstrated for the first time that the condition can be reversed by delivering a signal protein called vascular endothelial growth factor (VEGF) to the maternal side of the placenta, which is attached to the uterine lining; pregnant primates with elevated estrogen levels that were treated with this growth factor during the first trimester of pregnancy experienced an increase in uterine artery remodeling and were more likely to deliver normal weight babies compared to those who were not treated with VEGF.
“Our findings show that VEGF plays an important role in helping to promote proper blood flow to the placenta, which could help prevent pregnancy complications that occur with defective uterine artery remodeling,” said Eugene D. Albrecht, PhD, a Professor of Obstetrics, Gynecology and Reproductive Sciences at UMSOM and lead investigator on the study. “If our exciting finding can be replicated in pregnant women, VEGF could have the potential for preventing preeclampsia and other problems associated with placenta abnormalities.”
To conduct the study, Dr. Albrecht and his colleagues treated 17 pregnant female primates with daily estradiol (the female hormone estrogen) during the first several weeks of pregnancy to elevate their estrogen levels and suppress uterine artery remodeling. Six of those pregnant primates were also infused briefly via a peripheral vein in their arm with VEGF treatment four times during the first trimester of pregnancy; the treatment consisted of the gene for VEGF that was attached to tiny microbubbles that circulated throughout the bloodstream. During each infusion, the researchers directed a beam of sound waves delivered via a contrast-enhanced ultrasound transducer to the uterine arteries, which caused the microbubbles to burst. This freed the VEGF gene which could then bind to cell receptors in the placenta and uterine arteries, promoting a beneficial increase in uterine artery remodeling. (The microbubbles of VEGF that circulated elsewhere through the body were not activated, so VEGF would not have any unintended consequences on blood vessels other than in the uterus.)
Images of the uterine arteries revealed an increase in uterine artery remodeling in the primates that were treated with VEGF while those that received estrogen alone had a decrease in this remodeling. More importantly, the researchers found that blood flow through the placenta was reduced in those primates who were not treated with VEGF and that the body weight of the newborns was 10 percent lower on average.
VEGF is thought to increase uterine remodeling by increasing cell migration to artery walls where the cells do a renovation of sorts replacing smooth muscle cells and elastic fibers within the arteries to make them into less resistant to able to withstand a higher capacity of blood flow.
“This is the kind of cutting-edge science that defines our mission. This important new study provides vital evidence to explain one pathway that could lead to pregnancy-related complications, and we are eager to take the next step which is to replicate the research in pregnant women,” said E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean, University of Maryland School of Medicine.
Women who develop preeclampsia currently have few effective treatments beyond delivering the baby, which often must occur before the pregnancy has reached full term to reverse the sudden, dangerous rise in blood pressure. There are also few treatments to halt pre-term labor or treat fetal growth problems. These three conditions combined contribute to more than half of all medically induced deliveries before 35 weeks in the United States and are associated with disproportionately high rates of life-threatening complications and death in newborns.
Previous research has found an association between high estrogen levels, often resulting from fertility treatments, and the development of these placenta abnormalities in pregnant women, though other factors may also contribute including a family history and previous pregnancy complications involving the placenta.
Dr. Albrecht and his UMSOM colleagues who led the study have currently enrolled more than 100 pregnant patients in a new study where they are conducting 4-D ultrasound imaging to determine whether they can identify abnormalities in uterine artery remodeling early in human pregnancy. If that research has positive results, the researchers can then begin trials of VEGF treatments in pregnant women.
Researchers from Oregon Health and Science University, Buena Vista University, and Eastern Virginia Medical School also participated in this research, which was funded by the National Institutes of Health.
Source: Babischkin JS, Aberdeen GW, Lindner JR, Bonagura TW, Pepe GJ, Albrecht ED. “Vascular Endothelial Growth Factor Delivery to Placental Basal Plate Promotes Uterine Artery Remodeling in the Primate.” Endocrinology, 2019 Jun 1;160(6):1492-1505.
About the University of Maryland School of Medicine
Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 43 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished recipient of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for more than 1.2 million patients each year. The School has over 2,500 students, residents, and fellows, and more than $530 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total workforce of nearly 7,000 individuals. The combined School and Medical System (“University of Maryland Medicine”) has an annual budget of nearly $6 billion and an economic impact more than $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th highest among public medical schools in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu
About the University of Maryland Medical Center
The University of Maryland Medical Center (UMMC) is comprised of two hospitals in Baltimore: an 800-bed teaching hospital – the flagship institution of the 14-hospital University of Maryland Medical System (UMMS) – and a 200-bed community teaching hospital, UMMC Midtown Campus. UMMC is a national and regional referral center for trauma, cancer care, neurosciences, cardiac care, diabetes and endocrinology, women’s and children’s health, and has one of the largest solid organ transplant programs in the country. All physicians on staff at the flagship hospital are faculty physicians of the University of Maryland School of Medicine. At UMMC Midtown Campus, faculty physicians work alongside community physicians to provide patients with the highest quality care. UMMC Midtown Campus was founded in 1881 and is located one mile away from the University Campus hospital. For more information, visit www.umms.org/ummc.